This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n5http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n7http://linked.opendata.cz/resource/fda-spl/ingredient/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n6http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C2039
rdf:type
owl:Class
rdfs:label
Bevacizumab
owl:equivalentClass
_:vb630258
nci:A7
nci:C20450
nci:A8
nci:C63923
nci:P106
Amino Acid, Peptide, or Protein Pharmacologic Substance
nci:P108
Bevacizumab
nci:P175
704865
nci:P207
C0796392
nci:P210
216974-75-3
nci:P302
Metastatic Colorectal Cancer, Non-small Cell Lung Cancer, glioblastoma; Metastatic Renal Cell Carcinoma
nci:P303
Lung cancer; small cell and non-small cell; melanoma; mesothelioma; multiple myeloma; myelodysplastic syndromes; Non-Hodgkins lymphoma; pancreatic cancer; ovarian epithelial, fallopian tube, or primary peritoneal cancer Breast cancer; chronic myelogenous leukemia; cervical cancer; colorectal cancer; gastric cancer; gastroesophageal junction adenocarcinoma; head and neck cancer; hepatocellular carcinoma; Karposi sarcoma
nci:P319
2S9ZZM9Q9V
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
nci:P329
43234
nci:P330
43234
nci:P366
Bevacizumab
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Anti-VEGF</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0704865</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>rhuMab-VEGF</n0:term-name><n0:term-group>AB</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>bevacizumab</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000046115</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Anti-VEGF rhuMAb</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Avastin</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Avastin</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000367431</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>BEVACIZUMAB</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>2S9ZZM9Q9V</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Anti-VEGF Humanized Monoclonal Antibody</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Bevacizumab</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C2039
owl:sameAs
n6:N0000010546 n7:2S9ZZM9Q9V
n4:hasConcept
n5:M0443627
Subject Item
_:vb630258
rdf:type
owl:Class
owl:intersectionOf
_:vb739702
Subject Item
_:vb650290
rdf:type
owl:Restriction
owl:onProperty
nci:R72
owl:someValuesFrom
nci:C12865
Subject Item
_:vb650291
rdf:type
owl:Restriction
owl:onProperty
nci:R146
owl:someValuesFrom
nci:C20450
Subject Item
_:vb650292
rdf:type
owl:Restriction
owl:onProperty
nci:R124
owl:someValuesFrom
nci:C40474
Subject Item
_:vb650293
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C26044
Subject Item
_:vb650294
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C40579
Subject Item
_:vb650295
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C20751
Subject Item
_:vb650296
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C40821
Subject Item
_:vb739702
rdf:first
nci:C2496
rdf:rest
_:vb750722
Subject Item
_:vb750722
rdf:first
_:vb650290
rdf:rest
_:vb750723
Subject Item
_:vb750723
rdf:first
_:vb650291
rdf:rest
_:vb750724
Subject Item
_:vb750724
rdf:first
_:vb650292
rdf:rest
_:vb750725
Subject Item
_:vb750725
rdf:first
_:vb650293
rdf:rest
_:vb750726
Subject Item
_:vb750726
rdf:first
_:vb650294
rdf:rest
_:vb750727
Subject Item
_:vb750727
rdf:first
_:vb650295
rdf:rest
_:vb750728
Subject Item
_:vb750728
rdf:first
_:vb650296
rdf:rest
rdf:nil